Key Points
- Suvretta Capital Management, L acquired 1,481,481 shares of Benitec Biopharma on Nov. 7 at $13.50 per share, a ~$20.0 million purchase that increased its holding 18.39% to 9,538,175 shares (SEC Form 4 filed).
- Benitec (NASDAQ:BNTC) is a clinical‑stage biotech with a market cap of about $338 million; it reported a Q3 EPS loss of $0.42 (miss) and carries a consensus analyst rating of "Moderate Buy" with an average price target of $25.83 amid mixed recent upgrades and downgrades.
Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L acquired 1,481,481 shares of the company's stock in a transaction that occurred on Friday, November 7th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $19,999,993.50. Following the purchase, the director owned 9,538,175 shares of the company's stock, valued at $128,765,362.50. The trade was a 18.39% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Benitec Biopharma Stock Up 0.8%
BNTC opened at $12.89 on Tuesday. The company has a current ratio of 54.67, a quick ratio of 54.67 and a debt-to-equity ratio of 0.01. Benitec Biopharma Limited has a 12 month low of $9.10 and a 12 month high of $17.15. The company has a market cap of $338.36 million, a PE ratio of -8.77 and a beta of 0.23. The company has a 50 day moving average of $14.50 and a 200 day moving average of $13.76.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.18). On average, sell-side analysts expect that Benitec Biopharma Limited will post -1.48 EPS for the current year.
Institutional Investors Weigh In On Benitec Biopharma
Hedge funds have recently modified their holdings of the business. Infinitum Asset Management LLC boosted its stake in Benitec Biopharma by 435.7% in the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock valued at $14,636,000 after acquiring an additional 915,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Benitec Biopharma by 77.6% during the 2nd quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company's stock valued at $4,859,000 after purchasing an additional 181,391 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Benitec Biopharma by 219.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company's stock worth $1,286,000 after purchasing an additional 75,507 shares during the period. Goldman Sachs Group Inc. acquired a new position in Benitec Biopharma during the first quarter worth $597,000. Finally, Marshall Wace LLP purchased a new stake in Benitec Biopharma during the 2nd quarter worth approximately $503,000. Hedge funds and other institutional investors own 52.19% of the company's stock.
Analyst Upgrades and Downgrades
BNTC has been the topic of several recent analyst reports. HC Wainwright raised their target price on shares of Benitec Biopharma from $28.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, November 4th. Wall Street Zen cut shares of Benitec Biopharma from a "hold" rating to a "sell" rating in a report on Saturday. Zacks Research downgraded Benitec Biopharma from a "hold" rating to a "strong sell" rating in a report on Monday, October 6th. Oppenheimer reiterated an "outperform" rating and set a $29.00 target price (down from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. Finally, JMP Securities set a $22.00 target price on shares of Benitec Biopharma in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $25.83.
View Our Latest Report on Benitec Biopharma
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
